medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2021-17-37-42medalphabet-2109Research ArticleСтатьиЛекарственно-индуцированный панкреатит: фокус на препараты, применяющиеся для лечения заболеваний сердечно-сосудистой системыDrug-induced pancreatitis: focus on drugs used to treat cardiovascular diseasehttps://orcid.org/0000-0003-3081-602XФилипповаА. В.FilippovaA. V.

Филиппова Анастасия Витальевна, ординатор кафедры терапии и полиморбидной патологии.

Москва

Filippova Anastasia V., first-year intern of Dept of Therapy and Polymorbid Pathology.

Moscow

filippova.96@mail.ruhttps://orcid.org/0000-0002-0795-8225ОстроумоваО. Д.OstroumovaO. D.

Остроумова Ольга Дмитриевна, д. м. н., проф., зав. кафедрой терапии и полиморбидной патологии, проф. кафедры клинической фармакологии и пропедевтики внутренних болезней. eLibrary SPIN: 3910–6585

Москва

Ostroumova Olga D., DM Sci, professor, head of Dept of Therapy and Polymorbid Pathology, professor of Dept of Clinical Pharmacology and Propedeutics of Internal Diseases. eLibrary SPIN: 3910–6585

Moscow

ostroumova.olga@mail.ruФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy of Continuous Professional EducationRussian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России; ФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова» Минздрава России (Сеченовский университет)РоссияRussian Medical Academy of Continuous Professional Education; I.M. Sechenov First Moscow State Medical University (Sechenov University)Russian Federation202117082021017Кардиология и неотложная медицина (2)3742Copyright © Филиппова А.В., Остроумова О.Д., 20212021Филиппова А.В., Остроумова О.Д.Filippova A.V., Ostroumova O.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2109

Сердечно-сосудистые заболевания (ССЗ) являются основной причиной смерти во всем мире и в России. Поэтому остро стоит вопрос о безопасной и рациональной медикаментозной терапии. Но, как и большинство лекарственных средств (ЛС), препараты для лечения ССЗ имеют ряд нежелательных реакций, в частности развитие острого панкреатита. Эта НР может быть как дозозависимой, так и зависеть от длительности приема данных групп препаратов. Цель данного обзора – анализ литературных данных о лекарственных средствах, предназначенных для лечения сердечно-сосудистых заболеваний, которые могут приводить к развитию лекарственно-индуцированного панкреатита (ЛИП), о механизмах развития данной патологии на фоне приема конкретных ЛС, диагностике, лечении и профилактике. С развитием ЛИП ассоциирован прием диуретиков, как петлевых (фуросемида, этакриновой кислоты, буметамида), так и тиазидных или тиазидоподобных (хлоротиазида, гидрохлоротиазида и хлорталидона), антигипертензивных препаратов центрального действия (метилдопа), ингибиторов ангиотензинпревращающего фермента и блокаторов рецепторов к ангиотензину II, статинов, антиаритмических препаратов (амиодарона, прокаинамида). Литературные данные о развитии ЛИП представлены в большинстве публикаций описанием отдельных клинических случаев/серии случаев, однако в случае ЛИП, ассоциированного с приемом ИАПФ и статинов, имеются также данные когортных ретроспективных наблюдательных, проспективных наблюдательных по типу «случай – контроль», рандомизированных контролируемых исследований, метаанализов. При своевременной диагностике и отмене ЛС, ставших причиной развития острого панкреатита (ОП), симптомы заболевания регрессируют вплоть до полного исчезновения и развития серьезных последствий.

Cardiovascular diseases (CVD) are the leading cause of death worldwide and in Russia. Therefore, the question of safe and rational drug therapy is acute. But, like most drugs, drugs for the treatment of CVD have a number of adverse reactions, in particular, the development of acute pancreatitis. This adverse reactions can be both dose-dependent and depend on the duration of administration of these groups of drugs. The purpose of this review is to analyze the literature data on drugs intended for the treatment of СVD that can lead to the development of drug-induced pancreatitis (LIP), on the mechanisms of development of this pathology against the background of taking specific drugs, diagnosis, treatment and prevention. The development of LIP is associated with the use of diuretics, both loop (furosemide, etacric acid, bumetamide), and thiazide/thiazide-like (chlorothiazide, hydrochlorothiazide and chlorthalidone), antihypertensive drugs of central action (methyldopa), angiotensin converting enzyme inhibitors and angiotensin II receptor blockers, statins, antiarrhythmic drugs (amiodarone, procainamide). Literature data on the development of LIP are presented in most publications with the description of clinical case/series of cases, however, in the case of LIP associated with the use of ACEI and statins, there are also data from cohort, retrospective observational, prospective case-control, randomized controlled trials, and meta-analyses. With timely diagnosis, and the cancellation of drugs that have caused the development of OP, the symptoms of the disease regress until they completely disappear and develop serious consequences.

острый панкреатитлекарственно-индуцированный панкреатитлекарственное поражение поджелудочной железылекарственные средстванежелательные лекарственные реакцииacute pancreatitisdrug-induced pancreatitisdrug-induced pancreas injurydrugsadverse drug reactionReferencesLankisch P. G., Droge M., Gottesleben F. Drug induced pancreatitis: incidence and severity. Gut. 1995; 37 (4): 565–567. DOI: 10.1136/gut.37.4.565.Lankisch P. G., Droge M., Gottesleben F. Drug induced pancreatitis: incidence and severity. Gut. 1995; 37 (4): 565–567. DOI: 10.1136/gut.37.4.565.Официальный сайт Всемирной организации здравоохранения: 10 ведущих причин смерти в мире. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed 15 May 2021.Official website of the World Health Organization: Top 10 Causes of Death in the World. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/thetop-10-causes-of-death. Accessed 15 May 2021.Сычев Д. А. (ред.) Полипрагмазия в клинической практике: проблема и решения. Учебное пособие. 2-е изд., испр. и доп. СПб.: ЦОП «Профессия», 2018. 272 с., ил.Sychev D. A. (ed.) Polypharmacy in clinical practice: problem and solutions. Tutorial. 2nd ed., Rev. and add. SPb .: TsOP «Professiya», 2018. 272 p., Ill.Naranjo C.A,. Busto U., Sellers E. M., Sandor P., Ruiz I., Roberts E. A., Janecek E., Domecq C., Greenblatt D. J. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30 (2): 239–45. DOI: 10.1038/clpt.1981.154.Naranjo C.A,. Busto U., Sellers E. M., Sandor P., Ruiz I., Roberts E. A., Janecek E., Domecq C., Greenblatt D. J. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30 (2): 239–45. DOI: 10.1038/clpt.1981.154.Mallory A., Kern F. Jr. Drug-induced pancreatitis: a critical review. Gastroenterology. 1980; 78 (4): 813–820. DOI: 10.1016/0016–5085(80)90689–7.Mallory A., Kern F. Jr. Drug-induced pancreatitis: a critical review. Gastroenterology. 1980; 78 (4): 813–820. DOI: 10.1016/0016–5085(80)90689–7.Badalov N., Baradarian R., Iswara K., Li J., Steinberg W., Tenner S. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol. 2007; 5 (6): 648–661. DOI: 10.1016/j.cgh.2006.11.023.Badalov N., Baradarian R., Iswara K., Li J., Steinberg W., Tenner S. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol. 2007; 5 (6): 648–661. DOI: 10.1016/j.cgh.2006.11.023.Сычев Д.А, Остроумова О. Д., Переверзев А. П., Кочетков А. И., Остроумова Т. М., Клепикова М. В. и соавт. Лекарственно-индуцированные заболевания: подходы к диагностике, коррекции и профилактике. Фармаконадзор. Фармотека. 2020; 6: 113–126. doi:10.18565/pharmateca.2020.6.113–126.Sychev D. A., Ostroumova O. D., Pereverzev A. P., Kochetkov A. I. Ostroumova T. M., Klepikova M. V., et al. Drug-induced diseases: approaches to diagnosis, correction and prevention. Pharmacovigilance. Pharmoteca. 2020; 6: 113–126. (In Russ.) doi:10.18565/pharmateca.2020.6.113–126.Wilson A. E., Mehra S. K., Gomersall C. R., Davies D. M. Acute pancreatitis associated with frusemide therapy. Lancet. 1967; 289 (7481): 105. DOI: 10.1016/s0140-6736(67)92499–3.Wilson A. E., Mehra S. K., Gomersall C. R., Davies D. M. Acute pancreatitis associated with frusemide therapy. Lancet. 1967; 289 (7481): 105. DOI: 10.1016/s0140-6736(67)92499–3.Strunge P. Letter: Frusemide-induced pancreatitis? Journal Article. BMJ. 1975; 3 (5980): 434–434. doi:10.1136/bmj.3.5980.434-b.Strunge P. Letter: Frusemide-induced pancreatitis? Journal Article. BMJ. 1975; 3 (5980): 434–434. doi:10.1136/bmj.3.5980.434-b.Jones P. E., Oelbaum M. H. Frusemide-induced pancreatitis. Journal Article. 1975; 1 (5950): 133–134. doi:10.1136/bmj.1.5950.133.Jones P. E., Oelbaum M. H. Frusemide-induced pancreatitis. Journal Article. 1975; 1 (5950): 133–134. doi:10.1136/bmj.1.5950.133.Call T., Malarkey W. B., Thomas F. B. Acute pancreatitis secondary to furosemide with associated hyperlipidemia. The American Journal of Digestive Diseases. 1977; 22 (9): 835–838. doi:10.1007/bf01694517.Call T., Malarkey W. B., Thomas F. B. Acute pancreatitis secondary to furosemide with associated hyperlipidemia. The American Journal of Digestive Diseases. 1977; 22 (9): 835–838. doi:10.1007/bf01694517.Stenvinkel P., Vestrand A. Loop Diuretic-induced Pancreatitis with Rechallenge in a Patient with Malignant Hypertension and Renal Insufficiency. Acta Medica Scandinavica. 2009; 224 (1): 89–91. doi:10.1111/j.0954–6820.1988.tb16743.x.Stenvinkel P., Vestrand A. Loop Diuretic-induced Pancreatitis with Rechallenge in a Patient with Malignant Hypertension and Renal Insufficiency. Acta Medica Scandinavica. 2009; 224 (1): 89–91. doi:10.1111/j.0954–6820.1988.tb16743.x.Juang P., Page R. L., Zolty R. A Successful Rapid Desensitization Protocol in a Loop Diuretic Allergic Patient. Journal of Cardiac Failure. 2006; 40 (1): 128–34. doi:10.1345/aph.1g314.Juang P., Page R. L., Zolty R. A Successful Rapid Desensitization Protocol in a Loop Diuretic Allergic Patient. Journal of Cardiac Failure. 2006; 40 (1): 128–34. doi:10.1345/aph.1g314.Buchanan N., Cane R. D. Frusemid-induced pancreatitis. BMJ. 1977; 2 (6099): 1417–1417. doi:10.1136/bmj.2.6099.1417-c.Buchanan N., Cane R. D. Frusemid-induced pancreatitis. BMJ. 1977; 2 (6099): 1417–1417. doi:10.1136/bmj.2.6099.1417-c.Chao C. T., Chao J. Y. Case report: furosemide and pancreatitis: Importance of dose and latency period before reaction. Can Fam Physician. 2013; 59 (1): 43–45. doi:10.1007/s40278–013–5056–8.Chao C. T., Chao J. Y. Case report: furosemide and pancreatitis: Importance of dose and latency period before reaction. Can Fam Physician. 2013; 59 (1): 43–45. doi:10.1007/s40278–013–5056–8.Underwood T. W., Frye C. B. Drug-induced pancreatitis. Clin Pharm. 1993; 12 (6): 440–448. doi:10.1111/j.1365–2710.1993.tb00565.x.Underwood T. W., Frye C. B. Drug-induced pancreatitis. Clin Pharm. 1993; 12 (6): 440–448. doi:10.1111/j.1365–2710.1993.tb00565.x.Lynggaard E., Bjorndal N. Bumetanide-induced hyperamylaseaemia in patients with renal insufficiency. Lancet. 1977; 310 (8052): 1355. doi:10.1016/s0140–6736(77)90401–9.Lynggaard E., Bjorndal N. Bumetanide-induced hyperamylaseaemia in patients with renal insufficiency. Lancet. 1977; 310 (8052): 1355. doi:10.1016/s0140–6736(77)90401–9.Molnar J., Somberg J. C. The clinical pharmacology of ethacrynic acid. Am J Ther. 2009; 16 (1): 86–92. DOI: 10.1097/MJT.0b013e318195e460.Molnar J., Somberg J. C. The clinical pharmacology of ethacrynic acid. Am J Ther. 2009; 16 (1): 86–92. DOI: 10.1097/MJT.0b013e318195e460.Weaver G. A., Bordley J., Guiney W. B., D’Accurzio A. Chronic pancreatitis with cyst formation after prednisone and thiazide treatment. Am J Gastroenterol. 1982; 77 (3): 164–168. PMID: 7081177.Weaver G. A., Bordley J., Guiney W. B., D’Accurzio A. Chronic pancreatitis with cyst formation after prednisone and thiazide treatment. Am J Gastroenterol. 1982; 77 (3): 164–168. PMID: 7081177.Pickleman J, Straus F. H., Paloyan E. Pancreatitis Associated With Thiazide Administration. Archives of Surgery. 1979; 114 (9): 1013–1016. DOI: 10.1001/archsurg.1979.01370330035006.Pickleman J, Straus F. H., Paloyan E. Pancreatitis Associated With Thiazide Administration. Archives of Surgery. 1979; 114 (9): 1013–1016. DOI: 10.1001/archsurg.1979.01370330035006.Sammett D., Greben C., Sayeed-Shah U. Acute pancreatitis caused by penicillin. Dig Dis Sci. 1998; 43 (8): 1778–83. DOI: 10.1023/a:1018891905246.Sammett D., Greben C., Sayeed-Shah U. Acute pancreatitis caused by penicillin. Dig Dis Sci. 1998; 43 (8): 1778–83. DOI: 10.1023/a:1018891905246.Ludwig GD, Chaykin LD. Pancreatitis associated with primary hyperparathyroidism. Med Clin North Am. 1966; 50 (5): 1403–1418. doi:10.1016/s0025–7125(16)33133–9.Ludwig GD, Chaykin LD. Pancreatitis associated with primary hyperparathyroidism. Med Clin North Am. 1966; 50 (5): 1403–1418. doi:10.1016/s0025–7125(16)33133–9.Bolesta S., Montgomery P. Pancreatitis. Pharmacotherapy: a pathophysiologic approach. 9th Ed. 2014: 721–36.Bolesta S., Montgomery P. Pancreatitis. Pharmacotherapy: a pathophysiologic approach. 9th Ed. 2014: 721–36.Ances I. G., McClain C. A. Acute pancreatitis following the use of thiazide in pregnancy. South Med J. 1971; 64 (3): 267–9. DOI: 10.1097/00007611–197103000–00003.Ances I. G., McClain C. A. Acute pancreatitis following the use of thiazide in pregnancy. South Med J. 1971; 64 (3): 267–9. DOI: 10.1097/00007611–197103000–00003.Diamond M. T. Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis. N Y State J Med. 1972; 72 (13): 1741–2. doi:10.1001/jama.220.12.1592.Diamond M. T. Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis. N Y State J Med. 1972; 72 (13): 1741–2. doi:10.1001/jama.220.12.1592.Cohen L., Sandbank U., Rosenfeld J. B. Silent acute pancreatitis with encephalomalacia mimicking hepatic coma. Am J Gastroenterol. 1975; 63 (1): 75–78. PMID: 1119473.Cohen L., Sandbank U., Rosenfeld J. B. Silent acute pancreatitis with encephalomalacia mimicking hepatic coma. Am J Gastroenterol. 1975; 63 (1): 75–78. PMID: 1119473.Fuchs J. E., Keith M. R., Galanos A. N. Probable metolazone-induced pancreatitis. DICP. 1989; 23 (9): 711. DOI: 10.1177/106002808902300918.Fuchs J. E., Keith M. R., Galanos A. N. Probable metolazone-induced pancreatitis. DICP. 1989; 23 (9): 711. DOI: 10.1177/106002808902300918.Eckhauser M. L., Dokler M., Imbembo A. L. Diuretic-associated pancreatitis: a collective review and illustrative cases. Am J Gastroenterol. 1987; 82 (9): 865–70. PMID: 3631033.Eckhauser M. L., Dokler M., Imbembo A. L. Diuretic-associated pancreatitis: a collective review and illustrative cases. Am J Gastroenterol. 1987; 82 (9): 865–70. PMID: 3631033.Anderson P. E., Ellis G. G., Austin S. M. Case report: metolazone-associated hypercalcemia and acute pancreatitis. Am J Med Sci. 1991; 302 (4): 235–7. DOI: 10.1097/00000441–199110000–00008.Anderson P. E., Ellis G. G., Austin S. M. Case report: metolazone-associated hypercalcemia and acute pancreatitis. Am J Med Sci. 1991; 302 (4): 235–7. DOI: 10.1097/00000441–199110000–00008.Rion R. J. Recurrent pancreatitis after treatment with hydrochlorothiazide. J Am Board Fam Pract. 1994; 7 (1): 74–6. PMID: 7510925.Rion R. J. Recurrent pancreatitis after treatment with hydrochlorothiazide. J Am Board Fam Pract. 1994; 7 (1): 74–6. PMID: 7510925.Bedrossian S., Vahid B. A Case of Fatal Necrotizing Pancreatitis: Complication of Hydrochlorothiazide and Lisinopril Therapy. Dig Dis Sci. 2007; 52: 558–560. doi:10.1007/s10620–006–9220–3.Bedrossian S., Vahid B. A Case of Fatal Necrotizing Pancreatitis: Complication of Hydrochlorothiazide and Lisinopril Therapy. Dig Dis Sci. 2007; 52: 558–560. doi:10.1007/s10620–006–9220–3.Jones M. F., Caldwell J. R. Acute hemorrhagic pancreatitis associated with administration of chlorthalidone. Report of a case. N Engl J Med. 1962; 267: 1029–31. DOI: 10.1056/NEJM196211152672007.Jones M. F., Caldwell J. R. Acute hemorrhagic pancreatitis associated with administration of chlorthalidone. Report of a case. N Engl J Med. 1962; 267: 1029–31. DOI: 10.1056/NEJM196211152672007.Prigogine T. H., Futeral B., Kraytman M. Acute hemorrhagic pancreatitis associated with chlorthalidone therapy. Acta Clinica Belgica. 1978; 33 (4): 272–272. doi:10.1080/22953337.1978.11718641.Prigogine T. H., Futeral B., Kraytman M. Acute hemorrhagic pancreatitis associated with chlorthalidone therapy. Acta Clinica Belgica. 1978; 33 (4): 272–272. doi:10.1080/22953337.1978.11718641.Ibáñez L., Laporte J. R., Carné X. Adverse drug reactions leading to hospital admission. Drug Saf. 1991; 6 (6): 450–9. DOI: 10.2165/00002018–199106060–00005.Ibáñez L., Laporte J. R., Carné X. Adverse drug reactions leading to hospital admission. Drug Saf. 1991; 6 (6): 450–9. DOI: 10.2165/00002018–199106060–00005.Bruijn J. A., van Albada-Kuipers G.A., Smit V. T., Eulderink F. Acute pancreatitis in systemic lupus erythematosus. Scand J Rheumatol. 1986; 15 (4): 363–7. DOI: 10.3109/03009748609098204.Bruijn J. A., van Albada-Kuipers G.A., Smit V. T., Eulderink F. Acute pancreatitis in systemic lupus erythematosus. Scand J Rheumatol. 1986; 15 (4): 363–7. DOI: 10.3109/03009748609098204.Rominger J. M., Gutierrez J. G., Curtis D., Chey W. Y. Methyldopa-induced pancreatitis. Am J Dig Dis. 1978; 23 (8): 756–8. DOI: 10.1007/BF01072366.Rominger J. M., Gutierrez J. G., Curtis D., Chey W. Y. Methyldopa-induced pancreatitis. Am J Dig Dis. 1978; 23 (8): 756–8. DOI: 10.1007/BF01072366.Warren S. E., Mitas J. A., Swerdlin A. H. Pancreatitis Due to Methyldopa: Case Report. Military Medicine. 1980; 145 (6): 399–400. DOI: 10.1093/milmed/145.6.399.Warren S. E., Mitas J. A., Swerdlin A. H. Pancreatitis Due to Methyldopa: Case Report. Military Medicine. 1980; 145 (6): 399–400. DOI: 10.1093/milmed/145.6.399.Van der Heide H., Ten Haaft M. A., Stricker B. H. Pancreatitis caused by methyldopa. Clin Res Ed. 1981; 282 (6280): 1930–1. DOI: 10.1136/bmj.282.6280.1930.Van der Heide H., Ten Haaft M. A., Stricker B. H. Pancreatitis caused by methyldopa. Clin Res Ed. 1981; 282 (6280): 1930–1. DOI: 10.1136/bmj.282.6280.1930.DiMagno M.J., DiMagno E. P. Chronic pancreatitis. Curr Opin Gastroenterol. 2005; 21 (5): 544–54. DOI: 10.1097/01.mog.0000175543.42582.55.DiMagno M.J., DiMagno E. P. Chronic pancreatitis. Curr Opin Gastroenterol. 2005; 21 (5): 544–54. DOI: 10.1097/01.mog.0000175543.42582.55.Tilkemeier P., Thompson P. D. Acute pancreatitis possibly related to enalapril. N Engl J Med. 1988; 318 (19): 1275–6. DOI: 10.1056/NEJM198805123181914.Tilkemeier P., Thompson P. D. Acute pancreatitis possibly related to enalapril. N Engl J Med. 1988; 318 (19): 1275–6. DOI: 10.1056/NEJM198805123181914.Niebergall-Roth E., Teyssen S., Weber T., Singer M. V. Effect of 8-week administration of enalapril plus additional 2-week administration of furosemide on heart rate and exocrine pancreas secretion in dogs. Berl Munch Tierarztl Wochenschr. 1996; 109 (11–12): 414–8. PMID: 8999774.Niebergall-Roth E., Teyssen S., Weber T., Singer M. V. Effect of 8-week administration of enalapril plus additional 2-week administration of furosemide on heart rate and exocrine pancreas secretion in dogs. Berl Munch Tierarztl Wochenschr. 1996; 109 (11–12): 414–8. PMID: 8999774.Pedro-Botet J., Miralles R., Coll J., Rubiés-Prat J. Captopril versus Enalapril: Cough versus Pancreatitis. DICP. 1990; 24 (4): 438–439. doi:10.1177/106002809002400419.Pedro-Botet J., Miralles R., Coll J., Rubiés-Prat J. Captopril versus Enalapril: Cough versus Pancreatitis. DICP. 1990; 24 (4): 438–439. doi:10.1177/106002809002400419.Maringhini A., Termini A., Patti R., Ciambra M., Biffarella P., Pagliaro L. Enalapril-associated acute pancreatitis: recurrence after rechallenge. Am J Gastroenterol. 1997; 92 (1): 166–7. PMID: 8995963.Maringhini A., Termini A., Patti R., Ciambra M., Biffarella P., Pagliaro L. Enalapril-associated acute pancreatitis: recurrence after rechallenge. Am J Gastroenterol. 1997; 92 (1): 166–7. PMID: 8995963.Madsen J. S., Jacobsen I. A. Angiotensin converting enzyme inhibitor therapy and acute pancreatitis. Blood Press. 1995; 4 (6): 369–71. DOI: 10.3109/08037059509077623.Madsen J. S., Jacobsen I. A. Angiotensin converting enzyme inhibitor therapy and acute pancreatitis. Blood Press. 1995; 4 (6): 369–71. DOI: 10.3109/08037059509077623.Australian Adverse Drug Reaction Advisory Committee. Pancreatitis and ACE inhibitors. Australian Adverse Drug Reactions Bulletin. 1989.Australian Adverse Drug Reaction Advisory Committee. Pancreatitis and ACE inhibitors. Australian Adverse Drug Reactions Bulletin. 1989.Martin T., Taupignon A., Graf E., Perrin D. Pancreatitis and hepatitis in a patient treated with enalapril maleate. A case report. Therapie. 1989; 44 (6): 449–50. PMID: 2560267.Martin T., Taupignon A., Graf E., Perrin D. Pancreatitis and hepatitis in a patient treated with enalapril maleate. A case report. Therapie. 1989; 44 (6): 449–50. PMID: 2560267.González Ramallo V. J., Muiño Miguez A., Torres Segovia F. J. Necrotizing pancreatitis and enalapril. Eur J Med. 1992; 1 (2): 123. PMID: 1342370.González Ramallo V. J., Muiño Miguez A., Torres Segovia F. J. Necrotizing pancreatitis and enalapril. Eur J Med. 1992; 1 (2): 123. PMID: 1342370.Carnovale A., Esposito P., Bassano P., Russo L., Uomo G. Enalapril-induced acute recurrent pancreatitis. Dig Liver Dis. 2003; 35 (1): 55–7. DOI: 10.1016/s1590–8658(02)00012–9.Carnovale A., Esposito P., Bassano P., Russo L., Uomo G. Enalapril-induced acute recurrent pancreatitis. Dig Liver Dis. 2003; 35 (1): 55–7. DOI: 10.1016/s1590–8658(02)00012–9.Fisher A. A., Bassett M. L. Acute pancreatitis associated with angiotensin II receptor antagonists. Ann Pharmacother. 2002; 36 (12): 1883–6. DOI: 10.1345/aph.1C099.Fisher A. A., Bassett M. L. Acute pancreatitis associated with angiotensin II receptor antagonists. Ann Pharmacother. 2002; 36 (12): 1883–6. DOI: 10.1345/aph.1C099.Famularo G., Minisola G., Nicotra G. C., De Simone C. Acute pancreatitis associated with irbesartan therapy. Pancreas. 2005; 31 (3): 294–5. DOI: 10.1097/01.mpa.0000178281.58158.64.Famularo G., Minisola G., Nicotra G. C., De Simone C. Acute pancreatitis associated with irbesartan therapy. Pancreas. 2005; 31 (3): 294–5. DOI: 10.1097/01.mpa.0000178281.58158.64.Maliekal J., Drake C. F. Acute pancreatitis associated with the use of lisinopril. Ann Pharmacother. 1993; 27 (12): 1465–6. DOI: 10.1177/106002809302701211.Maliekal J., Drake C. F. Acute pancreatitis associated with the use of lisinopril. Ann Pharmacother. 1993; 27 (12): 1465–6. DOI: 10.1177/106002809302701211.Marinella M. A., Billi J. E. Lisinopril therapy associated with acute pancreatitis. West J Med. 1995; 163 (1): 77–8. PMID: 7667995.Marinella M. A., Billi J. E. Lisinopril therapy associated with acute pancreatitis. West J Med. 1995; 163 (1): 77–8. PMID: 7667995.Roush M. K., McNutt R.A., Gray T. F. The adverse effect dilemma: quest for accessible information. Ann Intern Med. 1991; 114 (4): 298–9. DOI: 10.7326/0003–4819–114–4–298.Roush M. K., McNutt R.A., Gray T. F. The adverse effect dilemma: quest for accessible information. Ann Intern Med. 1991; 114 (4): 298–9. DOI: 10.7326/0003–4819–114–4–298.Can B., Sali M., Batman A., Yilmaz H., Korkmaz U., Celebi A, Senturk O., et al. Valsartan-induced acute pancreatitis. Intern Med. 2014; 53 (7): 703–5. DOI: 10.2169/internalmedicine.53.0667.Can B., Sali M., Batman A., Yilmaz H., Korkmaz U., Celebi A, Senturk O., et al. Valsartan-induced acute pancreatitis. Intern Med. 2014; 53 (7): 703–5. DOI: 10.2169/internalmedicine.53.0667.Muchnick J. S., Mehta J. L. Angiotensin-converting enzyme inhibitor-induced pancreatitis. Clin Cardiol. 1999; 22 (1): 50–51. DOI: 10.1002/clc.4960220117.Muchnick J. S., Mehta J. L. Angiotensin-converting enzyme inhibitor-induced pancreatitis. Clin Cardiol. 1999; 22 (1): 50–51. DOI: 10.1002/clc.4960220117.Arjomand H., Kemp D. G. Quinapril and pancreatitis. Am J Gastroenterol. 1999; 94 (1): 290–1. PMID: 9934786.Arjomand H., Kemp D. G. Quinapril and pancreatitis. Am J Gastroenterol. 1999; 94 (1): 290–1. PMID: 9934786.Kanbay M., Selcuk H., Yilmaz U., Boyacioglu S. Recurrent acute pancreatitis probably secondary to lisinopril. South Med J. 2006; 99 (12): 1388–1389. DOI: 10.1097/01.smj.0000251413.20573.ad.Kanbay M., Selcuk H., Yilmaz U., Boyacioglu S. Recurrent acute pancreatitis probably secondary to lisinopril. South Med J. 2006; 99 (12): 1388–1389. DOI: 10.1097/01.smj.0000251413.20573.ad.Kanbay M., Korkmaz M., Yilmaz U., Gur G., Boyacioglu S. Acute pancreatitis due to ramipril therapy. Postgrad Med J. 2004; 80 (948): 617–618. DOI: 10.1136/pgmj.2003.018119.Kanbay M., Korkmaz M., Yilmaz U., Gur G., Boyacioglu S. Acute pancreatitis due to ramipril therapy. Postgrad Med J. 2004; 80 (948): 617–618. DOI: 10.1136/pgmj.2003.018119.Bracamonte J. D., Underhill M., Sarmiento P. Acute pancreatitis associated with lisinopril and olanzapine. Am J Health Syst Pharm. 2010; 67 (3): 214–216. DOI: 10.2146/ajhp080519.Bracamonte J. D., Underhill M., Sarmiento P. Acute pancreatitis associated with lisinopril and olanzapine. Am J Health Syst Pharm. 2010; 67 (3): 214–216. DOI: 10.2146/ajhp080519.Eland I. A., Sundström A., Velo G. P., Andersen M., Sturkenboom M. C., Langman M. J., Stricker B. H., et al. EDIP Study Group of the European Pharmacovigilance Research Group. Antihypertensive medication and the risk of acute pancreatitis: the European case-control study on drug-induced acute pancreatitis (EDIP). Scand J Gastroenterol. 2006; 41 (12): 1484–1490. DOI: 10.1080/00365520600761676.Eland I. A., Sundström A., Velo G. P., Andersen M., Sturkenboom M. C., Langman M. J., Stricker B. H., et al. EDIP Study Group of the European Pharmacovigilance Research Group. Antihypertensive medication and the risk of acute pancreatitis: the European case-control study on drug-induced acute pancreatitis (EDIP). Scand J Gastroenterol. 2006; 41 (12): 1484–1490. DOI: 10.1080/00365520600761676.Bexelius T. S., Ljung R., Fredrik Mattsson F., Lu Y., Lindblad M. Angiotensin II receptor blockers and risk of acute pancreatitis – a population based case–control study in Sweden. BMC Gastroenterology. 2017; 17 (1): 36. DOI: 10.1186/s12876–017–0595–8.Bexelius T. S., Ljung R., Fredrik Mattsson F., Lu Y., Lindblad M. Angiotensin II receptor blockers and risk of acute pancreatitis – a population based case–control study in Sweden. BMC Gastroenterology. 2017; 17 (1): 36. DOI: 10.1186/s12876–017–0595–8.Hung W. Y., Abreu Lanfranco O. Contemporary review of drug-induced pancreatitis: A different perspective. World J Gastrointest Pathophysiol. 2014; 5 (4): 405–415. DOI: 10.4291/wjgp.v5.i4.405.Hung W. Y., Abreu Lanfranco O. Contemporary review of drug-induced pancreatitis: A different perspective. World J Gastrointest Pathophysiol. 2014; 5 (4): 405–415. DOI: 10.4291/wjgp.v5.i4.405.Cheng R. M., Mamdani M., Jackevicius C. A., Tu K. Association between ACE inhibitors and acute pancreatitis in the elderly. Ann Pharmacother. 2003; 37 (7–8): 994–8. DOI: 10.1345/aph.1C270.Cheng R. M., Mamdani M., Jackevicius C. A., Tu K. Association between ACE inhibitors and acute pancreatitis in the elderly. Ann Pharmacother. 2003; 37 (7–8): 994–8. DOI: 10.1345/aph.1C270.Rozencweig M., McLaren C., Beltangady M., Ritter J., Canetta R., Schacter L., Kelley S., et al. Overview of phase I trials of 2’,3’-dideoxyinosine (ddI) conducted on adult patients. Rev Infect Dis. 1990; 12 (5): 570–575. DOI: 10.1093/clinids/12.supplement5.s570.Rozencweig M., McLaren C., Beltangady M., Ritter J., Canetta R., Schacter L., Kelley S., et al. Overview of phase I trials of 2’,3’-dideoxyinosine (ddI) conducted on adult patients. Rev Infect Dis. 1990; 12 (5): 570–575. DOI: 10.1093/clinids/12.supplement5.s570.Gershon T., Olshaker J. S. Acute pancreatitis following lisinopril rechallenge. Am J Emerg Med. 1998; 16 (5): 523–524. DOI: 10.1016/s0735–6757(98)90009–2.Gershon T., Olshaker J. S. Acute pancreatitis following lisinopril rechallenge. Am J Emerg Med. 1998; 16 (5): 523–524. DOI: 10.1016/s0735–6757(98)90009–2.Miller L. G., Tan G. Drug-induced pancreatitis (lisinopril). J Am Board Fam Pract. 1999; 12 (2): 150–153. DOI: 10.3122/jabfm.12.2.150.Miller L. G., Tan G. Drug-induced pancreatitis (lisinopril). J Am Board Fam Pract. 1999; 12 (2): 150–153. DOI: 10.3122/jabfm.12.2.150.Bi C. K., Soltani K., Sloan J. B. Induction of tissue-specific autoantibodies by captopril. Clin Res. 1988; 60 (10): 633–633. doi:10.1021/ac00161a728.Bi C. K., Soltani K., Sloan J. B. Induction of tissue-specific autoantibodies by captopril. Clin Res. 1988; 60 (10): 633–633. doi:10.1021/ac00161a728.Tisdale J. E., Miller D. A.. Drug-induced Diseases: Prevention, Detection, and Management. 3rd Ed. Bethesda. American Society of Health-System Pharmacists; 2018: 877–904.Tisdale J. E., Miller D. A.. Drug-induced Diseases: Prevention, Detection, and Management. 3rd Ed. Bethesda. American Society of Health-System Pharmacists; 2018: 877–904.Celbek G., Aydın Y, Ermiş F., Güngör A., Kutlucan A., Önder E. Rare Acute Pancreatitis Cases Due to Different Antihypertensive Drugs: Four Cases. Acta Medica Anatolia. 2014; 3 (X–X). doi:10.15824/actamedica.90033.Celbek G., Aydın Y, Ermiş F., Güngör A., Kutlucan A., Önder E. Rare Acute Pancreatitis Cases Due to Different Antihypertensive Drugs: Four Cases. Acta Medica Anatolia. 2014; 3 (X–X). doi:10.15824/actamedica.90033.Flati G., Andrén-Sandberg A., La Pinta M., Porowska B., Carboni M. Potentially fatal bleeding in acute pancreatitis: pathophysiology, prevention, and treatment. Pancreas. 2003; 26 (1): 8–14. DOI: 10.1097/00006676–200301000–00002.Flati G., Andrén-Sandberg A., La Pinta M., Porowska B., Carboni M. Potentially fatal bleeding in acute pancreatitis: pathophysiology, prevention, and treatment. Pancreas. 2003; 26 (1): 8–14. DOI: 10.1097/00006676–200301000–00002.Baffoni L., Durante V., Grossi M. Acute pancreatitis induced by telmisartan overdose. Ann Pharmacother. 2004; 38 (6): 1088. DOI: 10.1345/aph.1D582.Baffoni L., Durante V., Grossi M. Acute pancreatitis induced by telmisartan overdose. Ann Pharmacother. 2004; 38 (6): 1088. DOI: 10.1345/aph.1D582.Itidiare M., Rahman A., Nathan S. R., Ashraf S. Rosuvastatin-Induced Pancreatitis. American Journal of Gastroenterology. 2015; 110: 106. doi:10.14309/00000434-201510001–00245.Itidiare M., Rahman A., Nathan S. R., Ashraf S. Rosuvastatin-Induced Pancreatitis. American Journal of Gastroenterology. 2015; 110: 106. doi:10.14309/00000434-201510001–00245.Thisted H., Jacobsen J., Munk E. M., Nørgaard B., Friis S., McLaughlin J.K., Sørensen H. T., et al. Statins and the risk of acute pancreatitis: a population-based case-control study. Aliment Pharmacol Ther. 2006; 23 (1): 185–90. DOI: 10.1111/j.1365–2036.2006.02728.x.Thisted H., Jacobsen J., Munk E. M., Nørgaard B., Friis S., McLaughlin J.K., Sørensen H. T., et al. Statins and the risk of acute pancreatitis: a population-based case-control study. Aliment Pharmacol Ther. 2006; 23 (1): 185–90. DOI: 10.1111/j.1365–2036.2006.02728.x.Jones M. R., Hall O. M., Kaye A. M., Kaye A. D. Drug-induced acute pancreatitis: a review. Ochsner J. 2015; 15(1): 45–51. PMID: 25829880.Jones M. R., Hall O. M., Kaye A. M., Kaye A. D. Drug-induced acute pancreatitis: a review. Ochsner J. 2015; 15(1): 45–51. PMID: 25829880.Siwach V., Bansal V., Kumar A., Rao Ch U., Sharma A, M. Minz M. Post-renal transplant azathioprine-induced pancreatitis. Nephrology Dialysis Transplantation. 1999; 14 (10): 2495–2498. doi:10.1093/ndt/14.10.2495.Siwach V., Bansal V., Kumar A., Rao Ch U., Sharma A, M. Minz M. Post-renal transplant azathioprine-induced pancreatitis. Nephrology Dialysis Transplantation. 1999; 14 (10): 2495–2498. doi:10.1093/ndt/14.10.2495.Singh S., Loke Y. K. Statins and pancreatitis: a systematic review of observational studies and spontaneous case reports. Drug Saf. 2006; 29 (12): 1123–32. DOI: 10.2165/00002018–200629120–00004.Singh S., Loke Y. K. Statins and pancreatitis: a systematic review of observational studies and spontaneous case reports. Drug Saf. 2006; 29 (12): 1123–32. DOI: 10.2165/00002018–200629120–00004.Kuoppala J., Pulkkinen J., Kastarinen H., Kiviniemi V., Jyrkkä J., Enlund H., Happonen P., et al. Use of statins and the risk of acute pancreatitis: a population-based case-control study. Pharmacoepidemiol Drug Saf. 2015; 24 (10): 1085–92. DOI: 10.1002/pds.3858.Kuoppala J., Pulkkinen J., Kastarinen H., Kiviniemi V., Jyrkkä J., Enlund H., Happonen P., et al. Use of statins and the risk of acute pancreatitis: a population-based case-control study. Pharmacoepidemiol Drug Saf. 2015; 24 (10): 1085–92. DOI: 10.1002/pds.3858.Lai S. W., Lin C. L., Liao K. F. Atorvastatin Use Associated With Acute Pancreatitis: A Case-Control Study in Taiwan. Medicine (Baltimore). 2016; 95 (7): 2545. DOI: 10.1097/MD.0000000000002545.Lai S. W., Lin C. L., Liao K. F. Atorvastatin Use Associated With Acute Pancreatitis: A Case-Control Study in Taiwan. Medicine (Baltimore). 2016; 95 (7): 2545. DOI: 10.1097/MD.0000000000002545.Preiss D., Tikkanen M. J., Welsh P., Ford I., Lovato L. C., Elam M. B., La Rosa J. C., et al. Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA. 2012; 308 (8): 804–11. DOI: 10.1001/jama.2012.8439.Preiss D., Tikkanen M. J., Welsh P., Ford I., Lovato L. C., Elam M. B., La Rosa J. C., et al. Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA. 2012; 308 (8): 804–11. DOI: 10.1001/jama.2012.8439.Poropat G., Archibugi L., Korpela T., Cárdenas-Jaén K., de-Madaria E., Capurso G. Statin use is not associated with an increased risk of acute pancreatitis-A meta-analysis of observational studies. United European Gastroenterol J. 2018; 6 (8): 1206–1214. DOI: 10.1177/2050640618781168.Poropat G., Archibugi L., Korpela T., Cárdenas-Jaén K., de-Madaria E., Capurso G. Statin use is not associated with an increased risk of acute pancreatitis-A meta-analysis of observational studies. United European Gastroenterol J. 2018; 6 (8): 1206–1214. DOI: 10.1177/2050640618781168.Bosch X., Bernadich O. Acute pancreatitis during treatment with amiodarone. Lancet. 1997; 350 (9087): 1300. DOI: 10.1016/S0140–6736(05)62478–6.Bosch X., Bernadich O. Acute pancreatitis during treatment with amiodarone. Lancet. 1997; 350 (9087): 1300. DOI: 10.1016/S0140–6736(05)62478–6.Chen Y. Y., Chen C. Y., Leung K. K. Acute pancreatitis and amiodarone: a case report. World J Gastroenterol. 2007; 13 (6): 975–7. DOI: 10.3748/wjg.v13.i6.975.Chen Y. Y., Chen C. Y., Leung K. K. Acute pancreatitis and amiodarone: a case report. World J Gastroenterol. 2007; 13 (6): 975–7. DOI: 10.3748/wjg.v13.i6.975.Alonso A., MacLehose R.F., Lutsey P. L., Konety S., Chen L. Y. Association of amiodarone use with acute pancreatitis in patients with atrial fibrillation: a nested case-control study. JAMA Intern Med. 2015; 175 (3): 449–50. DOI: 10.1001/jamainternmed.2014.6927.Alonso A., MacLehose R.F., Lutsey P. L., Konety S., Chen L. Y. Association of amiodarone use with acute pancreatitis in patients with atrial fibrillation: a nested case-control study. JAMA Intern Med. 2015; 175 (3): 449–50. DOI: 10.1001/jamainternmed.2014.6927.Остроумова О. Д., Качан В. О. Лекарственно-индуцированный панкреатит. Лечебное Дело. 2020; 3: 14–24.Ostroumova O. D., Kachan V. O. Drug-induced pancreatitis. Medical Business. 2020; 3: 14–24. (In Russ.) DOI: 10.24412/2071–5315–2020–12251.

The authors declare that there are no conflicts of interest present.